AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14740125 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5‐fluorouracil
Number of subjects: 0
Study 14740125 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional administration of leucovorin or levamisole
Number of subjects: 0
Study 14740125 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with new drugs (capecitabine, UFT, irinotecan, oxaliplatin)
Number of subjects: 0
Study 14740125 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiochemotherapy for elderly patients
Number of subjects: 0
Study 11375842 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with 1:200,000 epinephrine
Number of subjects: 90
Study 11375842 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride (placebo)
Number of subjects: 90
Study 10980874 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWH)
Number of subjects: 0
Study 10980874 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 8674405 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg daily of tauroursodeoxycholic acid
Number of subjects: 24
Study 8674405 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg daily of tauroursodeoxycholic acid
Number of subjects: 24
Study 8674405 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg daily of tauroursodeoxycholic acid
Number of subjects: 24
Study 8674405 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea
Number of subjects: 24
Study 1455418 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypertension chemotherapy (IHC) with 5‐fluorouracil, adriamycin, and mitomycin C
Number of subjects: 13
Study 1455418 — intervention group
Group type: COMPARATOR
Intervention: Non-induced hypertension chemotherapy (same regimen without hypertension)
Number of subjects: 13
Study 1455418 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypertension chemotherapy (IHC)
Number of subjects: 13
Study 1455418 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between clinical and histological ratings
Number of subjects: 13
Study 6732937 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (apressine) 50-100 mg
Number of subjects: 12
Study 6732937 — intervention group
Group type: EXPERIMENTAL
Intervention: Endralazine (mirethilan) 5-15 mg
Number of subjects: 12
Study 6732937 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosine (pratsiol) 2-5 mg
Number of subjects: 12
Study 6732937 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (obsidan) 80-120 mg
Number of subjects: 12
Study 6732937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30031891 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Tilted Room (VTR)
Number of subjects: 20
Study 30031891 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-Weight Support Walking (BWSW)
Number of subjects: 20
Study 27112842 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH; 100 μg IV)
Number of subjects: 68
Study 27112842 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG; 4000 IU IM)
Number of subjects: 68
Study 25041868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intonation‐based speech therapy for 15 weeks
Number of subjects: 20
Study 25041868 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 20
Study 25041868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intonation‐based speech therapy
Number of subjects: 20
Study 22460943 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg wafer
Number of subjects: 80
Study 22460943 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 21239359 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir 300 mg twice daily
Number of subjects: 229
Study 21239359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 18051003 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal&Protect (Dentsply DeTrey GmbH)
Number of subjects: 60
Study 18051003 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivasens (Ivoclar Vivadent AG)
Number of subjects: 60
Study 18051003 — intervention group
Group type: EXPERIMENTAL
Intervention: BisBlock (BISCO)
Number of subjects: 60
Study 18051003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 60
Study 15618784 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 mg/kg succinylcholine
Number of subjects: 60
Study 15618784 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg succinylcholine
Number of subjects: 60
Study 15618784 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study 12406534 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum+COT
Number of subjects: 186
Study 12406534 — intervention group
Group type: COMPARATOR
Intervention: Sham+COT
Number of subjects: 186
Study 12406534 — intervention group
Group type: COMPARATOR
Intervention: nil+COT
Number of subjects: 186
Study 10588598 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg plus continuing inhaled beclomethasone
Number of subjects: 642
Study 10588598 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet plus continuing inhaled beclomethasone
Number of subjects: 642
Study 10588598 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg and inhaled placebo
Number of subjects: 642
Study 10588598 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet and inhaled placebo
Number of subjects: 642
Study 8546171 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (100 mg/day)
Number of subjects: 100
Study 8546171 — intervention group
Group type: COMPARATOR
Intervention: Control (no ketoconazole)
Number of subjects: 100
Study 2401123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propafenone (300 to 450 mg)
Number of subjects: 8
Study 2401123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (35 to 50 mg)
Number of subjects: 8
Study 2401123 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxy-propafenone (additive effect observed)
Number of subjects: 8
Study 31429383 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization splint worn by 23 patients
Number of subjects: 46
Study 31429383 — intervention group
Group type: COMPARATOR
Intervention: No intervention (follow-up without any intervention) for remaining subjects
Number of subjects: 46
Study 30471384 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE (10 × 1 min at 100% Vmax, 1 min recovery)
Number of subjects: 15
Study 30471384 — intervention group
Group type: COMPARATOR
Intervention: MICE (20 min at 55–59% VO2reserve)
Number of subjects: 15
Study 30121808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment with paclitaxel plus bevacizumab (2×4 cycles)
Number of subjects: 420
Study 30121808 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment with paclitaxel plus bevacizumab (8 cycles)
Number of subjects: 420
Study 30121808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment with paclitaxel plus bevacizumab
Number of subjects: 420
Study 30121808 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment with paclitaxel plus bevacizumab
Number of subjects: 420
Study 26761213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with pemetrexed and concurrent late course accelerated hyperfractionated radiotherapy (LCAHRT)
Number of subjects: 0
Study 26761213 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin with vinorelbine and concurrent late course accelerated hyperfractionated radiotherapy (LCAHRT)
Number of subjects: 0
Study 25261187 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training as an adjunct to conventional therapy
Number of subjects: 0
Study 25261187 — intervention group
Group type: COMPARATOR
Intervention: Dose-matched conventional training
Number of subjects: 0
Study 22296075 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ulipristal acetate
Number of subjects: 242
Study 22296075 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ulipristal acetate
Number of subjects: 242
Study 22296075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 21054824 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiation therapy (72 Gy E ± 5%)
Number of subjects: 0
Study 21054824 — intervention group
Group type: COMPARATOR
Intervention: Carbon ion radiation therapy (63 Gy E ± 5%)
Number of subjects: 0
Study 18762135 — intervention group
Group type: COMPARATOR
Intervention: Logo of the Netherlands Asthma Foundation
Number of subjects: 1938
Study 18762135 — intervention group
Group type: COMPARATOR
Intervention: Senior signature (director and professor)
Number of subjects: 1938
Study 16272621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium supplementation
Number of subjects: 0
Study 16272621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15189616 — intervention group
Group type: EXPERIMENTAL
Intervention: High anger feedback with projection allowed
Number of subjects: 0
Study 15189616 — intervention group
Group type: EXPERIMENTAL
Intervention: High dishonesty feedback with projection allowed
Number of subjects: 0
Study 15189616 — intervention group
Group type: COMPARATOR
Intervention: Low anger feedback
Number of subjects: 0
Study 15189616 — intervention group
Group type: COMPARATOR
Intervention: Low dishonesty feedback
Number of subjects: 0
Study 10331117 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 15
Study 10331117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8913468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 1 g
Number of subjects: 24
Study 8913468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 2 g
Number of subjects: 24
Study 8913468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 4 g
Number of subjects: 24
Study 8913468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (all doses)
Number of subjects: 24
Study 8913468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1905451 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25 mg irtemazole
Number of subjects: 12
Study 1905451 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg irtemazole
Number of subjects: 12
Study 1905451 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg irtemazole
Number of subjects: 12
Study 1905451 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg irtemazole
Number of subjects: 12
Study 1905451 — intervention group
Group type: EXPERIMENTAL
Intervention: irtemazole
Number of subjects: 12
Study 6132891 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol (15 mg daily)
Number of subjects: 11
Study 6132891 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (500 mg daily)
Number of subjects: 11
Study 6132891 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (500 mg daily) after 16 months
Number of subjects: 11
Study 31260419 — intervention group
Group type: EXPERIMENTAL
Intervention: TOTAL (whole-body split training routine with muscle groups trained 5 days per week)
Number of subjects: 18
Study 31260419 — intervention group
Group type: COMPARATOR
Intervention: SPLIT (muscle groups trained once per week)
Number of subjects: 18
Study 27510655 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic administration of 13C-labelled acetate
Number of subjects: 12
Study 27510655 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic administration of 13C-labelled propionate
Number of subjects: 12
Study 27510655 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic administration of 13C-labelled butyrate
Number of subjects: 12
Study 26717861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25mg, twice daily during the run-in period
Number of subjects: 72
Study 26717861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 72
Study 26717861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 24980672 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg once daily (n=9)
Number of subjects: 16
Study 24980672 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 5 mg once daily (n=7)
Number of subjects: 16
Study 24980672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Aliskiren and Ramipril)
Number of subjects: 16
Study 22271261 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional networks during seizures
Number of subjects: 3
Study 22271261 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-seizure changes in network properties
Number of subjects: 3
Study 22271261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic interactions of epileptic activities with the network
Number of subjects: 3
Study 18987057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE)
Number of subjects: 1054
Study 18987057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose infusion (LDI)
Number of subjects: 1054
Study 18987057 — intervention group
Group type: COMPARATOR
Intervention: High-dose bupivacaine (Control)
Number of subjects: 1054
Study 17891199 — intervention group
Group type: EXPERIMENTAL
Intervention: SLT after ALT
Number of subjects: 96
Study 17891199 — intervention group
Group type: EXPERIMENTAL
Intervention: SLT
Number of subjects: 96
Study 17891199 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT
Number of subjects: 96
Study 14871429 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA trough levels measured at day 2 posttransplant
Number of subjects: 334
Study 14871429 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA trough levels lower than 300 ng/mL
Number of subjects: 334
Study 14871429 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA trough values
Number of subjects: 334
Study 14871429 — intervention group
Group type: COMPARATOR
Intervention: C2 levels considered alone
Number of subjects: 334
Study 12238832 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg tranexamic acid (TA) followed by infusion of 1 mg/kg per hour during the operation
Number of subjects: 50
Study 12238832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 50
Study 9589246 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Number of subjects: 8
Study 9589246 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 8
Study 9589246 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 8
Study 7977174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg p.o. 1 hour prior to chemotherapy, repeated after 6 and 12 hours plus dexamethasone 20 mg i.v. 40 minutes prior to chemotherapy
Number of subjects: 64
Study 7977174 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide, dexamethasone, and orphenadrine (Control)
Number of subjects: 64
Study 7977174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg PO t.i.d. days 2 and 3
Number of subjects: 64
Study 7977174 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 0.5 mg/kg p.o. q.i.d. and dexamethasone 8 mg i.m. b.i.d. days 2 and 3 (Control)
Number of subjects: 64
Study 7977174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondex
Number of subjects: 64
Study 7977174 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study 2683904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent external negative pressure ventilation (ENPV) with the Emerson Pulmowrap ventilator during a 3-week in-hospital pulmonary rehabilitation program (Group II)
Number of subjects: 16
Study 2683904 — intervention group
Group type: COMPARATOR
Intervention: In-hospital pulmonary rehabilitation program without ENPV (Group I)
Number of subjects: 16
Study 2683904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 16
Study 31676898 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-to-clinic navigator intervention
Number of subjects: 345
Study 31676898 — intervention group
Group type: COMPARATOR
Intervention: Group education (comparison group)
Number of subjects: 345
Study 28071929 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (n = 18)
Number of subjects: 53
Study 28071929 — intervention group
Group type: COMPARATOR
Intervention: Fit Brains® (n = 19)
Number of subjects: 53
Study 28071929 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (n = 16)
Number of subjects: 53
Study 27316489 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg/kg of magnesium sulfate (MS) in 100ml 0.9% NaCl solution over 20min before anesthesia induction (Group A)
Number of subjects: 600
Study 27316489 — intervention group
Group type: COMPARATOR
Intervention: 100ml 0.9% NaCl solution (Group B)
Number of subjects: 600
Study 26353411 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg day(-1))
Number of subjects: 42
Study 26353411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22625877 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg every 12 h for 4 days with a single 15 mg dose of pioglitazone on day 3
Number of subjects: 30
Study 22625877 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone alone (15 mg)
Number of subjects: 30
Study 22625877 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil with pioglitazone
Number of subjects: 30
Study 21130476 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting
Number of subjects: 894
Study 21130476 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvesting
Number of subjects: 894
Study 18841790 — intervention group
Group type: EXPERIMENTAL
Intervention: CRSwNP group (n=10)
Number of subjects: 10
Study 18841790 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 10
Study 15905227 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein preload plus ID saline perfusion
Number of subjects: 20
Study 15905227 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein preload plus ID fat perfusion
Number of subjects: 20
Study 15905227 — intervention group
Group type: COMPARATOR
Intervention: Water preload plus ID saline perfusion
Number of subjects: 20
Study 15905227 — intervention group
Group type: COMPARATOR
Intervention: Water preload plus ID fat perfusion
Number of subjects: 20
Study 11895545 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% P‐113 mouthrinse
Number of subjects: 294
Study 11895545 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% P‐113 mouthrinse
Number of subjects: 294
Study 11895545 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 294
Study 10399449 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU group (preoperative treatment aiming at a CI >= 4.0 l/min/m2)
Number of subjects: 31
Study 10399449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special treatment)
Number of subjects: 31
Study 7551323 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL-2 (12 x 10(6) IU/m2/day)
Number of subjects: 19
Study 7551323 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study 2076441 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (4 drops of a 5% solution every 8 hours)
Number of subjects: 40
Study 2076441 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local treatment)
Number of subjects: 40
Study 7033789 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine (250 mg four times a day)
Number of subjects: 52
Study 7033789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to D-penicillamine)
Number of subjects: 52
Study 30703070 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual plus verbal feedback
Number of subjects: 38
Study 30703070 — intervention group
Group type: COMPARATOR
Intervention: Verbal feedback only
Number of subjects: 38
Study 30703070 — intervention group
Group type: EXPERIMENTAL
Intervention: High neuroticism
Number of subjects: 38
Study 30703070 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscientiousness and agreeableness
Number of subjects: 38
Study 28682725 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate silver dressing (Ag group)
Number of subjects: 39
Study 28682725 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution gauze (NSS group)
Number of subjects: 39
Study 26404298 — intervention group
Group type: EXPERIMENTAL
Intervention: RF generated M-VLTR shock
Number of subjects: 30
Study 26404298 — intervention group
Group type: EXPERIMENTAL
Intervention: RF generated B-VLTR shock
Number of subjects: 30
Study 26404298 — intervention group
Group type: EXPERIMENTAL
Intervention: RF generated M-VLTR or B-VLTR shock
Number of subjects: 30
Study 23566765 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 - as-machined
Number of subjects: 32
Study 23566765 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 - glazed
Number of subjects: 32
Study 23566765 — intervention group
Group type: EXPERIMENTAL
Intervention: G3 - diamond bur finishing
Number of subjects: 32
Study 23566765 — intervention group
Group type: EXPERIMENTAL
Intervention: G4 - G3 + OptraFine(®) polishing kit
Number of subjects: 32
Study 21440461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 50
Study 21440461 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 50
Study 19606450 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization method using a spreadsheet
Number of subjects: 0
Study 19606450 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization database
Number of subjects: 0
Study 18083374 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)
Number of subjects: 0
Study 18083374 — intervention group
Group type: COMPARATOR
Intervention: Wide margins, elective lymph node dissection, sentinel lymph node (SLN) biopsy, prophylactic isolated limb perfusion (ILP)
Number of subjects: 0
Study 18083374 — intervention group
Group type: COMPARATOR
Intervention: Systemic adjuvant therapy
Number of subjects: 0
Study 18083374 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapeutic drugs, immunostimulants, and various vaccines
Number of subjects: 0
Study 15122604 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 60